share_log

Cantor Fitzgerald Reiterates Overweight on Abeona Therapeutics, Maintains $38 Price Target

Benzinga ·  Jul 13, 2023 08:56

Cantor Fitzgerald analyst Kristen Kluska reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and maintains $38 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment